Division of Hematology, Department of Pediatrics.
Comprehensive Bone Marrow Failure Center, Division of Hematology, and.
Blood Adv. 2020 Oct 27;4(20):5232-5245. doi: 10.1182/bloodadvances.2020002687.
Inherited bone marrow failure (IBMF) syndromes are rare blood disorders characterized by hematopoietic cell dysfunction and predisposition to hematologic malignancies. Despite advances in the understanding of molecular pathogenesis of these heterogeneous diseases, genetic variant interpretation, genotype-phenotype correlation, and outcome prognostication remain difficult. As new IBMF and other myelodysplastic syndrome (MDS) predisposition genes continue to be discovered (frequently in small kindred studies), there is an increasing need for a systematic framework to evaluate penetrance and prevalence of mutations in genes associated with IBMF phenotypes. To address this need, we analyzed population-based genomic data from >125 000 individuals in the Genome Aggregation Database for loss-of-function (LoF) variants in 100 genes associated with IBMF. LoF variants in genes associated with IBMF/MDS were present in 0.426% of individuals. Heterozygous LoF variants in genes in which haploinsufficiency is associated with IBMF/MDS were identified in 0.422% of the population; homozygous LoF variants associated with autosomal recessive IBMF/MDS diseases were identified in only .004% of the cohort. Using age distribution of LoF variants and 2 measures of mutational constraint, LOEUF ("loss-of-function observed/expected upper bound fraction") and pLI ("probability of being loss-of-function intolerance"), we evaluated the pathogenicity, tolerance, and age-related penetrance of LoF mutations in specific genes associated with IBMF syndromes. This analysis led to insights into rare IBMF diseases, including syndromes associated with DHX34, MDM4, RAD51, SRP54, and WIPF1. Our results provide an important population-based framework for the interpretation of LoF variant pathogenicity in rare and emerging IBMF syndromes.
遗传性骨髓衰竭 (IBMF) 综合征是一类罕见的血液疾病,其特征为造血细胞功能障碍和易患血液系统恶性肿瘤。尽管人们对这些异质性疾病的分子发病机制的认识有所提高,但遗传变异的解释、基因型-表型相关性以及预后预测仍然具有挑战性。随着新的 IBMF 和其他骨髓增生异常综合征 (MDS) 易感性基因(经常在小家族研究中发现)的不断发现,人们越来越需要一个系统的框架来评估与 IBMF 表型相关的基因中的突变的外显率和流行率。为了满足这一需求,我们分析了来自 125000 多名个体的基于人群的基因组数据,这些个体来自于基因组聚合数据库,研究了与 IBMF 相关的 100 个基因中的无功能 (LoF) 变异。与 IBMF/MDS 相关的基因中的 LoF 变异在 0.426%的个体中存在。与 IBMF/MDS 相关的基因中杂合性 LoF 变异在人群中占 0.422%;与常染色体隐性 IBMF/MDS 疾病相关的纯合性 LoF 变异仅在队列中占.004%。我们使用 LoF 变异的年龄分布和 2 种突变约束度量(LOEUF 和 pLI),评估了与 IBMF 综合征相关的特定基因中的 LoF 突变的致病性、耐受性和与年龄相关的外显率。这种分析为罕见的 IBMF 疾病提供了深入的了解,包括与 DHX34、MDM4、RAD51、SRP54 和 WIPF1 相关的综合征。我们的研究结果为解释罕见和新兴的 IBMF 综合征中的 LoF 变异的致病性提供了一个重要的基于人群的框架。